MedPath

Caffeine

Generic Name
Caffeine
Brand Names
Anacin, Arthriten Inflammatory Pain, Ascomp, Bc Arthritis, Bc Original Formula, Cafcit, Diurex, Dvorah, Esgic, Exaprin, Excedrin, Excedrin Tension Headache, Fioricet, Fioricet With Codeine, Fiorinal, Goody's Extra Strength, Goody's Headache Relief Shot, Goody's PM, Midol Complete, Midol Cramps & Bodyaches, Migergot, Norgesic, Norgesic Forte, Orbivan, Orphengesic, Pamprin Max Formula, Peyona, Stanback Headache Powder Reformulated Jan 2011, Trezix, Trianal, Trianal C, Triatec, Triatec-8, Vanatol, Vanatol S, Vanquish, Vivarin, Peyona (previously Nymusa), Gencebok
Drug Type
Small Molecule
Chemical Formula
C8H10N4O2
CAS Number
58-08-2
Unique Ingredient Identifier
3G6A5W338E
Background

Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to Theophylline and Theobromine. It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans. Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection.

The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999. According to an article from 2017, more than 15 million babies are born prematurely worldwide. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a condition that interferes with lung development and may eventually cause asthma or early onset emphysema in those born prematurely. Caffeine is beneficial in preventing and treating apnea and bronchopulmonary dysplasia in newborns, improving the quality of life of premature infants.

Indication

Caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth. In addition, it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with CNS depressant drugs. Caffeine has a broad range of over the counter uses, and is found in energy supplements, athletic enhancement products, pain relief products, as well as cosmetic products.

Associated Conditions
Acute Pain, Chronic Lung Disease of Prematurity, Common Cold, Dyspepsia, Fatigue, Fever, Flu caused by Influenza, Headache, Menstrual Pain, Myalgia, Pain, Pain caused by Rheumatism, Primary apnea of premature newborns, Respiratory Depression, Somnolence, Tension Headache, Toothache, Under-eyes Dark Circles, Vascular Headaches, Moderate Pain
Associated Therapies
Analgesia, Antacid therapy, Athletic Performance

Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity

Not Applicable
Not yet recruiting
Conditions
Brown Adipose Tissue (BAT) Physiology
Cold Exposure
Interventions
First Posted Date
2025-05-18
Last Posted Date
2025-05-18
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
12
Registration Number
NCT06978777
Locations
πŸ‡¨πŸ‡­

University Hospital Basel, Department of Endocrinology, Basel, Switzerland

Caffeine Citrate to Improve Neonatal Outcomes.

Not Applicable
Not yet recruiting
Conditions
Apnea of Prematurity
Interventions
First Posted Date
2025-05-15
Last Posted Date
2025-05-15
Lead Sponsor
University of Melbourne
Target Recruit Count
3900
Registration Number
NCT06972849

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

Phase 1
Recruiting
Conditions
Advanced Chronic Liver Disease
Healthy Participants
Interventions
First Posted Date
2025-05-15
Last Posted Date
2025-05-18
Lead Sponsor
AstraZeneca
Target Recruit Count
16
Registration Number
NCT06973005
Locations
πŸ‡ΊπŸ‡Έ

Research Site, Brooklyn, Maryland, United States

CAffeine Use in Prolonged Oxygen Use in meConium aspIration Syndrome in Neonatal Outcomes (CAPUCINO)

Phase 2
Not yet recruiting
Conditions
Meconium Aspiration Syndrome
Interventions
Other: Saline (NaCl 0,9 %) (placebo)
First Posted Date
2025-05-14
Last Posted Date
2025-05-14
Lead Sponsor
University of Alberta
Target Recruit Count
20
Registration Number
NCT06972108

A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

Phase 1
Recruiting
Conditions
RSV Infection
Drug Drug Interaction
Interventions
First Posted Date
2025-04-08
Last Posted Date
2025-04-08
Lead Sponsor
Enanta Pharmaceuticals, Inc
Target Recruit Count
24
Registration Number
NCT06917508
Locations
πŸ‡ΊπŸ‡Έ

ICON, plc, San Antonio, Texas, United States

To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers

Phase 1
Recruiting
Conditions
Healty Volunteers
Interventions
First Posted Date
2025-02-12
Last Posted Date
2025-04-04
Lead Sponsor
Kaken Pharmaceutical
Target Recruit Count
36
Registration Number
NCT06821698
Locations
πŸ‡ΊπŸ‡Έ

Parexel International Early Phase Clinical Unit, Glendale, California, United States

Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI

Phase 4
Recruiting
Conditions
Healthy
Caffeine
Adenosine
Dopamine D2/3 Receptor Availability
Interventions
First Posted Date
2025-01-08
Last Posted Date
2025-01-09
Lead Sponsor
Hsiao-Ying Wey
Target Recruit Count
12
Registration Number
NCT06763172
Locations
πŸ‡ΊπŸ‡Έ

Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, United States

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

First Posted Date
2024-11-13
Last Posted Date
2024-12-27
Lead Sponsor
Sanofi
Target Recruit Count
20
Registration Number
NCT06686628
Locations
πŸ‡©πŸ‡ͺ

Investigational Site Number : 2760001, Berlin, Germany

Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia

Not Applicable
Completed
Conditions
Hypercapnia
Interventions
Other: Graded hypercapnia
Drug: Placebo
First Posted Date
2024-10-11
Last Posted Date
2024-10-11
Lead Sponsor
United States Army Research Institute of Environmental Medicine
Target Recruit Count
29
Registration Number
NCT06636825
Locations
πŸ‡ΊπŸ‡Έ

US Army Research Institute of Environmental Medicine, Natick, Massachusetts, United States

A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

Phase 1
Active, not recruiting
Conditions
Drug Drug Interaction (DDI)
Interventions
First Posted Date
2024-10-09
Last Posted Date
2025-02-07
Lead Sponsor
Allyx Therapeutics
Target Recruit Count
36
Registration Number
NCT06632990
Locations
πŸ‡ΊπŸ‡Έ

Spaulding Clinical Research, West Bend, Wisconsin, United States

Β© Copyright 2025. All Rights Reserved by MedPath